Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Debt Ratio (2016 - 2026)

Heron Therapeutics filings provide 6 years of Debt Ratio readings, the most recent being 0.44 for Q1 2026.

  • On a quarterly basis, Debt Ratio rose 311.31% to 0.44 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.44, a 311.31% increase, with the full-year FY2025 number at 0.42, up 292.85% from a year prior.
  • Debt Ratio hit 0.44 in Q1 2026 for Heron Therapeutics, up from 0.42 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.44 in Q1 2026 to a low of 0.1 in Q3 2023.
  • Median Debt Ratio over the past 4 years was 0.11 (2024), compared with a mean of 0.21.
  • Biggest five-year swings in Debt Ratio: fell 4.68% in 2025 and later surged 311.31% in 2026.
  • Heron Therapeutics' Debt Ratio stood at 0.11 in 2023, then dropped by 1.56% to 0.11 in 2024, then surged by 292.85% to 0.42 in 2025, then grew by 4.32% to 0.44 in 2026.
  • The last three reported values for Debt Ratio were 0.44 (Q1 2026), 0.42 (Q4 2025), and 0.43 (Q3 2025) per Business Quant data.